申请人:Novo Nordisk A/S
公开号:US05430027A1
公开(公告)日:1995-07-04
Adenosine compounds having the following structure ##STR1## wherein X is halogen, perhalomethyl, acetamido, cyano, C.sub.1-6 -alkoxy, C.sub.1-6 -alkylthio or C.sub.1-6 -alkylamino; and R.sup.1 is --NR.sup.2 R.sup.3 or YR.sup.4, wherein Y is oxygen or sulfur; R.sup.2 is phenyl, C.sub.1-6 -alkyl or substituted C.sub.1-6 -alkyl; and R.sup.4 is naphthyl, partly saturated naphthyl; optionally phenyl or phenoxy substituted C.sub.1-6 -alkyl wherein the phenyl and phenoxy substituents are also optionally substituted, or optionally phenyl or phenoxy substituted C.sub.3-8 -cycloalkyl and their pharmaceutically acceptable salts are useful in the treatment of myocardial and cerebral ischemias.
腺苷化合物具有以下结构##STR1##其中X是卤素、全氟甲基、乙酰氨基、氰基、C.sub.1-6-烷氧基、C.sub.1-6-烷硫基或C.sub.1-6-烷基胺基;R.sup.1是--NR.sup.2 R.sup.3或YR.sup.4,其中Y是氧或硫;R.sup.2是苯基、C.sub.1-6-烷基或取代的C.sub.1-6-烷基;R.sup.4是萘基、部分饱和的萘基;可选择地为取代的苯基或苯氧基的C.sub.1-6-烷基,其中苯基和苯氧基取代基也可选择地被取代,或可选择地为取代的苯基或苯氧基的C.sub.3-8-环烷基及其药用盐在治疗心肌和脑缺血中是有用的。